A Review of Therapeutic Escalation for Pediatric Patients Admitted for Inflammatory Bowel Disease Flares.

ABSTRACT:

Objectives

The objective was to complete a single hospital quality assessment to characterize the use, safety, and outcomes of the 5 specialty medications (infliximab, adalimumab, tofacitinib, ustekinumab, and vedolizumab) used for the treatment of pediatric inflammatory bowel disease following admission due to a disease flare.

Methods

This was a single-center, retrospective, quality assessment of the current clinical practice. The electronic medical record was queried to identify patients ages 0 to 18 years admitted to our institution during a 2-year period from September 1, 2019, to September 30, 2021, who received infliximab, adalimumab, tofacitinib, ustekinumab, and/or vedolizumab for the treatment of Crohn's disease or ulcerative colitis followed by manual data collecti

SUBMITTER: Koubek DN 

PROVIDER: S-EPMC10681080 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature